EPS for Cel-Sci (CVM)

EPS in 2025 (TTM): -₹953.27

According to Cel-Sci 's latest financial reports the company's current EPS (TTM) is -₹1,037. an increase over its 2024 EPS that were of -₹1,413.

EPS history for Cel-Sci from 1996 to 2025

Annual EPS

Year	EPS	Change
2025	-₹578.72	-59.05%
2024	-₹1,413	-30.09%
2023	-₹2,021	-16.09%
2022	-₹2,409	-3.33%
2021	-₹2,492	9.76%
2020	-₹2,271	15.49%
2019	-₹1,966	-62.03%
2018	-₹5,178	2.19%
2017	-₹5,067	-22.78%
2016	-₹6,563	-77.45%
2015	-₹29,102	-13.14%
2014	-₹33,505	61.33%
2013	-₹20,768	-57.14%
2012	-₹48,458	-45.31%
2011	-₹88,608	-420%
2010	₹27,690	-112.9%
2009	-₹2,14,598	342.86%
2008	-₹48,458	-30%
2007	-₹69,225	-0%
2006	-₹69,225	150%
2005	-₹27,690	-0%
2004	-₹27,690	-75%
2003	-₹1,10,760	-54.29%
2002	-₹2,42,288	-31.37%
2001	-₹3,53,048	15.91%
2000	-₹3,04,590	-15.38%
1999	-₹3,59,970	-29.73%
1998	-₹5,12,265	-26%
1997	-₹6,92,250	-13.79%
1996	-₹8,03,010

EPS for similar companies or competitors

Company	EPS	EPS differencediff.	Country
Johnson & Johnson JNJ	₹1,028	-199.09%	🇺🇸 USA
Amgen AMGN	₹1,323	-227.49%	🇺🇸 USA
Xencor XNCR	-₹163.37	-84.25%	🇺🇸 USA
Curis CRIS	-₹338.74	-67.35%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	₹114.45	-111.03%	🇮🇱 Israel
BioCryst Pharmaceuticals BCRX	-₹4.62	-99.56%	🇺🇸 USA
Emergent BioSolutions EBS	₹130.14	-112.54%	🇺🇸 USA
Eterna Therapeutics ERNA	-₹7,080	582.47%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions